



**HRUSKA, KEITH A.** Professor of Pediatrics, Medicine, and Cell Biology, Washington University, St. Louis, Missouri, USA

Place of Birth: Sidney, Nebraska, USA

Education/Training/Positions: MD, Creighton University, Omaha, Nebraska, 1969; Intern and Resident, Department of Medicine, Cornell University, New York Hospital, Manhattan, New York, 1969-1971; Resident, Department of Medicine, Washington University, St. Louis, Missouri, 1971-1972; National Institutes of Health (NIH) Postdoctoral Fellow in Nephrology, Washington University, 1972-1974; Instructor, Assistant Professor, Associate Professor, and Professor,

Departments of Medicine and Cell Biology/Biophysics, Washington University, 1974-present; Director, Renal Division, Barnes Jewish Hospital, Washington University, 1979-1994; Co-Director, Renal Division, Barnes Jewish Hospital, Washington University, 1994-1998; Ira M. Lang Professor of Medicine in Nephrology, Washington University, 1988-2001; Medical Director, Mid-America Transplant Services, St. Louis, Missouri, 1976-present; Member, Bone and Mineral Division, Department of Medicine, Washington University, 1980-present; Professor of Pediatrics, Director of Pediatric Nephrology, Washington University, 2001-present; Founder, Scientific Advisory Board Chairman, and Board of Directors' Medical Advisor, Isto Technologies, 2004-present

Honors/Awards: Alpha Omega Alpha Honor Medical Society, 1969; NIH Fellowship, Washington University, 1972-1973; National Kidney Foundation Fellowship, Washington University, 1974; Established Investigator Award, American Heart Association, 1979-1984; Ira M. Lang Endowed Chair in Nephrology, 1988-2001, American Society for Clinical Investigation, 1984; Association of American Physicians, 1990

Editorial Duties/Peer Review Panels: Editor: *American Journal of Physiology: Renal, Fluid and Electrolyte Physiology*, 1989-1995; *Calcified Tissue International*, 2000-2004; Editorial Boards: *Calcified Tissue International*, 2000-2004; *Journal of Bone and Mineral Research*, 2003-2006; *Bone*, 2004-2007; Member, Orthopedics and Musculoskeletal Studies Study Section, NIH, 1987-1991; Member, General Medicine B (GMB) Study Section, NIH, 1992-1996; Ad Hoc Member, GMB Oral Biology and Medicine and Orthopedics Study Sections, NIH, 1997-2002; Chair, Musculoskeletal Integrated Review Group Boundaries Panel, NIH, 1999-2001; Ad Hoc Member, Pathobiology of Kidney Disease Study Section, NIH, 2003-2004; Ad Hoc Member, Skeletal Biology Development and Disease Study Section, NIH, 2004; Member, Skeletal Biology Development and Disease Study Section, NIH, 2004-present

Professional Societies: Member: ASBMR; American Physiological Society; American Society for Cell Biology; American Society for Clinical Investigation; American Society of Nephrology (ASN); Association of American Physicians; International Bone and Mineral Society; Orthopaedic Research Society; Member.; Chair, Young Investigator Award Committee, ASN, 1998-2000; Secretary Treasurer, ASBMR, 2006-2009

Current Research: Basic bone cell biology; Chronic kidney disease-mineral bone disorder (CKD-MBD); vascular calcification and phosphorus as a cardiovascular risk factor; cartilage bioengineering and bone anabolic factors, especially the bone morphogenetic proteins

Statement of Interest: I have been a member of the Society since its inception and served as Secretary-Treasurer 2006-2009. I was a council member from 1983-1986 and a member of the education Committee, 1983-1988. I am a chapter author of our Primer, and I have served on the editorial boards of the JBMR, Bone and CTI. I have been an Editor of CTI. I am an active investigator in the fields of bone cell biology as described above. My current focus is in the vascular calcification of the CKD-MBD which has contributed to the discovery of phosphorus as a cardiovascular risk factor, through determining its mechanism of action.

I look forward to the opportunity to serve the society as it leads the pursuit of the causes and treatment of metabolic bone disorders and diseases. The Society has matured in its role and supported the development of a strong scientific base in both basic and clinical research. Recently, the Society has witnessed major recent scientific advances and changes in its environment with the economic recession of 2007-8. Also, the emergence of major abuses associated with relationships to industry leading to new rules and scrutiny governing corporate relations and conflict of interest will have new impact on the ASBMR. Our publishing enterprise has been revamped, and our website redone and modernized. During this recent past of significant developments and accomplishments, our revenues have diminished, and our expenses have held steady. As a result, we now struggle to operate a balanced budget. New sources of revenue are required to maintain our vigor, and continue the pursuit of our mission.

There remains much the society should accomplish. Though we have participated in the clinical definition and development of treatments for several of our diseases, much still needs to be done. Osteoporosis is not at the level of public consciousness that it requires, osteoarthritis is poorly understood and undertreated, and osteoporosis is seriously undertreated. These major shortfalls in the public consciousness and in medical practice of our field require the society to take on a new vigorous role in leading the clinical treatment of metabolic bone diseases. While these are not entirely new directions for the ASBMR, they are new areas of

emphasis and can serve to provide invigoration and freshness to the pursuit of conquering our diseases. As I stand for election, I look forward to supporting the ASBMR in its future endeavors, and I am grateful to the Society for the role it has played in my career.

Disclosures: Celgene 2; Fresenius 1; Genzyme 1; Isto Technologies 5; Shire 1, 2; Stryker 2

*The following numerical key was used to characterize the potential conflicts of interest listed in the “Disclosures” section above.*

- 1. research grants or financial support from commercial entities*
- 2. consultant or member of advisory board to a commercial entity*
- 3. participant in a speakers bureau*
- 4. employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
- 5. stock holdings in pharmaceutical, medical device, or diagnostic companies*
- 6. any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization’s board, or committee, or serves on its journal, etc.)*